296 related articles for article (PubMed ID: 18381962)
21. High prevalence of retinoblastoma protein loss in triple-negative breast cancers and its association with a good prognosis in patients treated with adjuvant chemotherapy.
Treré D; Brighenti E; Donati G; Ceccarelli C; Santini D; Taffurelli M; Montanaro L; Derenzini M
Ann Oncol; 2009 Nov; 20(11):1818-23. PubMed ID: 19556322
[TBL] [Abstract][Full Text] [Related]
22. Y-box binding protein, YB-1, as a marker of tumor aggressiveness and response to adjuvant chemotherapy in breast cancer.
Huang J; Tan PH; Li KB; Matsumoto K; Tsujimoto M; Bay BH
Int J Oncol; 2005 Mar; 26(3):607-13. PubMed ID: 15703814
[TBL] [Abstract][Full Text] [Related]
23. Lack of TIMP-1 tumour cell immunoreactivity predicts effect of adjuvant anthracycline-based chemotherapy in patients (n=647) with primary breast cancer. A Danish Breast Cancer Cooperative Group Study.
Willemoe GL; Hertel PB; Bartels A; Jensen MB; Balslev E; Rasmussen BB; Mouridsen H; Ejlertsen B; Brünner N
Eur J Cancer; 2009 Sep; 45(14):2528-36. PubMed ID: 19535243
[TBL] [Abstract][Full Text] [Related]
24. Influence of thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms on the disease-free survival of breast cancer patients receiving adjuvant 5-fluorouracil/methotrexate-based therapy.
Paré L; Altés A; Ramón y Cajal T; Del Rio E; Alonso C; Sedano L; Barnadas A; Baiget M
Anticancer Drugs; 2007 Aug; 18(7):821-5. PubMed ID: 17581305
[TBL] [Abstract][Full Text] [Related]
25. Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy.
Rudas M; Lehnert M; Huynh A; Jakesz R; Singer C; Lax S; Schippinger W; Dietze O; Greil R; Stiglbauer W; Kwasny W; Grill R; Stierer M; Gnant MF; Filipits M;
Clin Cancer Res; 2008 Mar; 14(6):1767-74. PubMed ID: 18347178
[TBL] [Abstract][Full Text] [Related]
26. p53 as a specific prognostic factor in triple-negative breast cancer.
Chae BJ; Bae JS; Lee A; Park WC; Seo YJ; Song BJ; Kim JS; Jung SS
Jpn J Clin Oncol; 2009 Apr; 39(4):217-24. PubMed ID: 19304743
[TBL] [Abstract][Full Text] [Related]
27. Acquisition of multidrug resistance in recurrent breast cancer demonstrated by the histoculture drug response assay.
Tanino H; Oura S; Hoffman RM; Kubota T; Furukawa T; Arimoto J; Yoshimasu T; Hirai I; Bessho T; Suzuma T; Sakurai T; Naito Y
Anticancer Res; 2001; 21(6A):4083-6. PubMed ID: 11911296
[TBL] [Abstract][Full Text] [Related]
28. [Evaluation of 5-fluorouracil-related genes in breast cancer to predict the effect of adjuvant therapy with CMF].
Tsunoda Y; Suzuki K; Sakamoto MA; Date Y; Sawada T; Tsunoda A; Kusano M
Gan To Kagaku Ryoho; 2009 Jan; 36(1):51-5. PubMed ID: 19151563
[TBL] [Abstract][Full Text] [Related]
29. Implications for improved high-dose methotrexate therapeutic effects in cultured human breast cancer and bone marrow cells.
Bowen D; Southerland WM; Johnson DH; Hawkins M; Hughes DE
Cancer Detect Prev; 2000; 24(5):452-8. PubMed ID: 11129987
[TBL] [Abstract][Full Text] [Related]
30. Gene expression profilers and conventional clinical markers to predict distant recurrences for premenopausal breast cancer patients after adjuvant chemotherapy.
Niméus-Malmström E; Ritz C; Edén P; Johnsson A; Ohlsson M; Strand C; Ostberg G; Fernö M; Peterson C
Eur J Cancer; 2006 Nov; 42(16):2729-37. PubMed ID: 17023159
[TBL] [Abstract][Full Text] [Related]
31. Methylated NEUROD1 promoter is a marker for chemosensitivity in breast cancer.
Fiegl H; Jones A; Hauser-Kronberger C; Hutarew G; Reitsamer R; Jones RL; Dowsett M; Mueller-Holzner E; Windbichler G; Daxenbichler G; Goebel G; Ensinger C; Jacobs I; Widschwendter M
Clin Cancer Res; 2008 Jun; 14(11):3494-502. PubMed ID: 18519782
[TBL] [Abstract][Full Text] [Related]
32. Sequential combination chemotherapy in human breast cancer: a basis for increased antineoplastic activity and bone marrow protection.
Davis JH; Desoto JA; Fryar EB; Southerland WM; Bowen D
Cell Mol Biol (Noisy-le-grand); 2007 May; 53(3):18-26. PubMed ID: 17531145
[TBL] [Abstract][Full Text] [Related]
33. Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts.
Paulus P; Stanley ER; Schäfer R; Abraham D; Aharinejad S
Cancer Res; 2006 Apr; 66(8):4349-56. PubMed ID: 16618760
[TBL] [Abstract][Full Text] [Related]
34. Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897.
Ganz PA; Hussey MA; Moinpour CM; Unger JM; Hutchins LF; Dakhil SR; Giguere JK; Goodwin JW; Martino S; Albain KS
J Clin Oncol; 2008 Mar; 26(8):1223-30. PubMed ID: 18227530
[TBL] [Abstract][Full Text] [Related]
35. Expression of sigma 1 receptor in human breast cancer.
Wang B; Rouzier R; Albarracin CT; Sahin A; Wagner P; Yang Y; Smith TL; Meric-Bernstam F; Marcelo Aldaz C; Hortobagyi GN; Pusztai L
Breast Cancer Res Treat; 2004 Oct; 87(3):205-14. PubMed ID: 15528963
[TBL] [Abstract][Full Text] [Related]
36. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.
Li X; Lewis MT; Huang J; Gutierrez C; Osborne CK; Wu MF; Hilsenbeck SG; Pavlick A; Zhang X; Chamness GC; Wong H; Rosen J; Chang JC
J Natl Cancer Inst; 2008 May; 100(9):672-9. PubMed ID: 18445819
[TBL] [Abstract][Full Text] [Related]
37. Long-term outcome of adjuvant chemotherapy cyclophosphamide, mitoxantrone, and fluorouracil in women with breast cancer.
Kumpulainen EJ; Hirvikoski PP; Johansson RT
Acta Oncol; 2008; 47(1):120-3. PubMed ID: 18097780
[TBL] [Abstract][Full Text] [Related]
38. Mitogen-activated protein kinase phosphatase-1 in human breast cancer independently predicts prognosis and is repressed by doxorubicin.
Rojo F; González-Navarrete I; Bragado R; Dalmases A; Menéndez S; Cortes-Sempere M; Suárez C; Oliva C; Servitja S; Rodriguez-Fanjul V; Sánchez-Pérez I; Campas C; Corominas JM; Tusquets I; Bellosillo B; Serrano S; Perona R; Rovira A; Albanell J
Clin Cancer Res; 2009 May; 15(10):3530-9. PubMed ID: 19417026
[TBL] [Abstract][Full Text] [Related]
39. Expression of the high-affinity fluoropyrimidine-preferring nucleoside transporter hCNT1 correlates with decreased disease-free survival in breast cancer.
Gloeckner-Hofmann K; Guillén-Gómez E; Schmidtgen C; Porstmann R; Ziegler R; Stoss O; Casado FJ; Rüschoff J; Pastor-Anglada M
Oncology; 2006; 70(3):238-44. PubMed ID: 16837820
[TBL] [Abstract][Full Text] [Related]
40. Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines.
Jiang Y; Tong D; Lou G; Zhang Y; Geng J
Pathobiology; 2008; 75(4):244-51. PubMed ID: 18580070
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
